On 15 October 2014, orphan designation (EU/3/14/1342) was granted by the European Commission to S-cubed Limited, United Kingdom, for glucagon for the treatment of congenital hyperinsulinism.
Treatment of congenital hyperinsulinism
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|January 2019||The sponsorship was transferred to S-cubed Pharmaceutical Services ApS, Denmark, in January 2019.|
|June 2023||The sponsor’s address was updated in June 2023.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: